Vertex Pharmaceuticals Incorporated

12/01/2021 | Press release | Distributed by Public on 12/01/2021 06:39

Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis